Medical treatment would be more widely available to opioid abusers under a rare bipartisan measure aimed at tackling the U.S. addiction crisis expected to be signed into law by President Trump.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
U.S. Food and Drug Administration Commissioner Scott Gottlieb announced that the regulatory agency is relaunching the Drug Competition Action Plan in 2019 with some additional initiatives.
The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.
Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States during September 2018, following a recall of much of the drug’s supply.
The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, will propose requiring companies to include the price of Rx medicines in TV ads.
President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.
Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.
Merck & Co. CEO Kenneth Frazier, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.
Seattle Genetics and development partner Takeda Pharmaceutical announced stellar Phase III data from the ECHELON-2 clinical trial of Adcetris (brentuximab vedotin) for peripheral T-cell lymphoma.